Rationale and Design of the Adaptresponse Trial: A Prospective Randomized Study of Cardiac Resynchronization Therapy with Preferential Adaptive Left Ventricular-Only Pacing
Key result
The AdaptResponse trial is designed to randomize approximately 3,000 patients to evaluate whether the AdaptivCRT algorithm reduces all-cause mortality and HF decompensation versus conventional CRT.
Why the study?
Does a CRT system with the AdaptivCRT algorithm reduce the composite of all-cause mortality and intervention for HF decompensation compared to conventional CRT in patients with a CRT indication, LBBB, and normal AV conduction?
Population
Approximately 3,000 patients with a cardiac resynchronization therapy indication, left bundle branch block…
Comparison
CRT system containing the AdaptivCRT algorithm vs Conventional CRT
Design
RCT, 1:1 fashion, single-blinded
Follow-up
event-driven
Authors
Discussion
Loading...
Member takes
Implication
Supports adaptive CRT in LBBB patients with normal AV conduction; extends randomized evidence for optimized resynchronization.
Study Design
Type
RCT (n=3,000)
Blinding
Single-blind
Randomization
1:1
Multicenter
Yes
Structured PICO
Does a CRT system with the AdaptivCRT algorithm reduce the composite of all-cause mortality and intervention for HF decompensation compared to conventional CRT in patients with a CRT indication, LBBB, and normal AV conduction?
P
Population
Approximately 3,000 patients with a CRT indication, LBBB, and normal AV conduction to be randomized in an event-driven trial.
I
Intervention
CRT system containing the AdaptivCRT algorithm (preferential adaptive left ventricular-only pacing)
C
Comparator
Conventional CRT
O
Outcome
Composite of all-cause mortality and intervention for heart failure (HF) decompensation (event-driven, targeting 1100 events)composite
The AdaptResponse trial is designed to determine if the AdaptivCRT algorithm improves clinical outcomes compared to conventional CRT in patients with LBBB and normal AV conduction.
Cite This Study
Filippatos et al. (2017) conducted an RCT in Heart failure (n=3,000). AdaptivCRT algorithm vs. Conventional CRT was evaluated on Composite of all-cause mortality and intervention for HF decompensation. The AdaptResponse trial is designed to randomize approximately 3,000 patients to evaluate whether the AdaptivCRT algorithm reduces all-cause mortality and HF decompensation versus conventional CRT.